PDF(Pubmed)
Abstract：
Cannabinoid type 1 receptor (CB1R), as the major member of the endocannabinoid system, is among the most abundant receptors expressed in the central nervous system. CB1R is mainly located on the axon terminals of presynaptic neurons and participate in the modulation of neuronal excitability and synaptic plasticity, playing an important role in the pathogenesis of various neuropsychiatric diseases. In recent years, the consistent development of CB1R radioligands and the maturity of molecular imaging techniques, particularly positron emission tomography (PET) may help to visualize the expression and distribution of CB1R in central nervous system . At present, CB1R PET imaging can effectively evaluate the changes of CB1R levels in neuropsychiatric diseases such as Huntington\'s disease and schizophrenia, and its correlation with the disease severity, therefore providing new insights for the diagnosis and treatment of neuropsychiatric diseases. This article reviews the application of CB1R PET imaging in Alzheimer\'s disease, Parkinson\'s disease, Huntington\'s disease, schizophrenia, post-traumatic stress disorder, cannabis use disorder and depression.
摘要：
大麻素1型受体（CB1R），作为内源性大麻素系统的主要成员，是中枢神经系统中表达最丰富的受体之一。CB1R主要位于突触前神经元的轴突末端,参与神经元兴奋性和突触可塑性的调节,在各种神经精神疾病的发病机制中起着重要作用。近年来,CB1R放射性配体的不断发展和分子成像技术的成熟，尤其是正电子发射断层扫描（PET）可能有助于可视化CB1R在中枢神经系统中的表达和分布。目前,CB1RPET显像能有效评估亨廷顿病、精神分裂症等神经精神疾病患者CB1R水平的变化,以及它与疾病严重程度的相关性，从而为神经精神疾病的诊断和治疗提供新的见解。本文综述了CB1RPET显像在阿尔茨海默病中的应用。帕金森病,亨廷顿病,精神分裂症,创伤后应激障碍,大麻使用障碍和抑郁症。
